{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T21:04:08Z","timestamp":1772571848161,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":4116,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1093\/annonc\/mdn165","type":"journal-article","created":{"date-parts":[[2008,4,27]],"date-time":"2008-04-27T00:14:30Z","timestamp":1209255270000},"page":"1541-1546","source":"Crossref","is-referenced-by-count":33,"title":["Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer"],"prefix":"10.1016","volume":"19","author":[{"given":"F.","family":"Puglisi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.G.","family":"Cardellino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Crivellari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Di Loreto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.D.","family":"Magri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Minisini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mansutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Andreetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Perin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Damante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Veronesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdn165_bb0010","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdn165_bb0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1470-2045(05)01766-3","article-title":"Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment","volume":"6","author":"Toi","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdn165_bb0020","first-page":"1013","article-title":"Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol\/taxotere in human cancer xenografts","volume":"4","author":"Sawada","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdn165_bb0025","first-page":"945","article-title":"Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients","volume":"7","author":"Kurosumi","year":"2000","journal-title":"Oncol Rep"},{"key":"10.1093\/annonc\/mdn165_bb0030","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1038\/sj.bjc.6601845","article-title":"Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer","volume":"90","author":"Toi","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdn165_bb0035","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/CAD.0b013e32816ebede","article-title":"Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells","volume":"18","author":"Puglisi","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdn165_bb0040","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results","volume":"20","author":"O'Shaughnessy","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn165_bb0045","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/annonc\/mdl134","article-title":"Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?","volume":"17","author":"Leonard","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdn165_bb0050","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1200\/JCO.2002.22.030","article-title":"Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies","volume":"20","author":"Nadella","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn165_bb0055","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdn165_bb0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1023\/B:BREA.0000036797.86601.cc","article-title":"Reproducible immunohistochemical criteria based on multiple raters' judgments for expression of thymidine phosphorylase in breast cancer tissue","volume":"86","author":"Tsuda","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdn165_bb0065","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdn165_bb0070","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn165_bb0075","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00024669-200605020-00004","article-title":"First-line treatment of metastatic breast cancer: available evidence and current recommendations","volume":"5","author":"Puglisi","year":"2006","journal-title":"Am J Cancer"},{"key":"10.1093\/annonc\/mdn165_bb0080","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3816\/CBC.2004.n.032","article-title":"Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer","volume":"5","author":"Mackey","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdn165_bb0085","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00280-004-0909-8","article-title":"Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies","volume":"55","author":"Ramanathan","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdn165_bb0090","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3816\/CBC.2006.n.023","article-title":"Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer","volume":"7","author":"Mrozek","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdn165_bb0095","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1200\/JCO.2004.12.128","article-title":"Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study","volume":"22","author":"Gradishar","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn165_bb0100","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1200\/JCO.2005.05.1383","article-title":"Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer","volume":"24","author":"Blum","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn165_bb0105","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3816\/CBC.2007.n.003","article-title":"Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy","volume":"7","author":"Blum","year":"2007","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdn165_bb0110","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000100449","article-title":"Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK","volume":"71","author":"Gick","year":"2006","journal-title":"Oncology"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419402044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419402044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/19\/9\/1541\/544152\/mdn165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:39:29Z","timestamp":1624437569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419402044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0923753419402044"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdn165","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}